Literature DB >> 27252265

Complement levels and anti-C1q autoantibodies in patients with neuropsychiatric systemic lupus erythematosus.

C Magro-Checa1, R A Schaarenburg2, H J L Beaart2, T W J Huizinga2, G M Steup-Beekman2, L A Trouw2.   

Abstract

OBJECTIVE: The objective of this paper is to analyse serum levels of anti-C1q, C1q circulating immune complexes (CIC), complement activation and complement components in systemic lupus erythematosus (SLE) patients during the first central nervous system neuropsychiatric (NP) event and to define the possible association between these results and clinical and laboratory characteristics.
METHODS: A total of 280 patients suspected of having NP involvement due to SLE were recruited in the Leiden NPSLE-clinic. All SLE patients were classified according to the ACR 1982 revised criteria for the classification of SLE. The clinical disease activity was measured by the SLE Disease Activity Index 2000 (SLEDAI-2K) and NP diagnoses were classified according to the 1999 ACR case definitions for NPSLE. We measured in serum of all patients anti-C1q and C1q CIC levels, the activation capacity of complement (CH50 and AP50) and different complement components (C1q, C3, C4).
RESULTS: In 92 patients the symptoms were attributed to SLE. NPSLE patients consisted of 63 patients with focal NPSLE and 34 patients with diffuse NPSLE. Anti-C1q antibodies were significantly higher and CH50, AP50 and C3 were significantly lower in NPSLE patients compared with SLE patients without NPSLE. This association was specially marked for diffuse NPSLE while no differences were found for focal NPSLE. After using potential predictors, decreased C4 remained significantly associated with focal NPSLE, but only when antiphospholipid antibodies (aPL) were included in the model. C3 and AP50 were independently associated with diffuse NPSLE. When SLEDAI-2K was included in the model these two associations were lost. When individual NPSLE syndromes were analysed, psychosis and cognitive dysfunction showed significantly lower values of complement activation capacity and all complement components. No significant associations were seen for other individual NPSLE syndromes.
CONCLUSION: The associations between diffuse NPSLE and anti-C1q, C3/AP50 and focal NPSLE and C4 may be explained by disease activity and the presence of aPL, respectively. The role of complement activation and complement components in lupus psychosis and cognitive dysfunction merits further research.
© The Author(s) 2016.

Entities:  

Keywords:  Neuropsychiatric systemic lupus erythematosus; SLE; alternative complement pathway; anti-C1q antibody; complement

Mesh:

Substances:

Year:  2016        PMID: 27252265     DOI: 10.1177/0961203316643170

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  9 in total

1.  Mycophenolate mofetil and deflazacort combination in neuropsychiatric lupus: a decade of experience from a tertiary care teaching hospital in southern India.

Authors:  Nikhil Gupta; Arvind Ganpati; Santosh Mandal; John Mathew; Ruchika Goel; Ashish Jacob Mathew; Aswin Nair; Prakash Ramasamy; Debashish Danda
Journal:  Clin Rheumatol       Date:  2017-08-07       Impact factor: 2.980

Review 2.  Cognitive Dysfunction in Systemic Lupus Erythematosus: Immunopathology, Clinical Manifestations, Neuroimaging and Management.

Authors:  Dominic Seet; Nur Azizah Allameen; Jiacai Cho; Anselm Mak; Sen Hee Tay
Journal:  Rheumatol Ther       Date:  2021-05-15

Review 3.  Neuropsychiatric Systemic Lupus Erythematosus Involvement: Towards a Tailored Approach to Our Patients?

Authors:  Raquel Faria; João Gonçalves; Rita Dias
Journal:  Rambam Maimonides Med J       Date:  2017-01-30

4.  Are serum autoantibodies associated with brain changes in systemic lupus erythematosus? MRI data from the Leiden NP-SLE cohort.

Authors:  C Magro-Checa; S Kumar; S Ramiro; L J Beaart-van de Voorde; J Eikenboom; I Ronen; J de Bresser; M A van Buchem; T W Huizinga; G M Steup-Beekman
Journal:  Lupus       Date:  2018-12-08       Impact factor: 2.911

5.  Comparative proteomics analysis of plasma protein in patients with neuropsychiatric systemic lupus erythematosus.

Authors:  Chen Chen; Linyu Geng; Xue Xu; Wei Kong; Yayi Hou; Genhong Yao; Xuebing Feng; Huayong Zhang; Jun Liang
Journal:  Ann Transl Med       Date:  2020-05

6.  Overexpression of FcγRIIB regulates downstream protein phosphorylation and suppresses B cell activation to ameliorate systemic lupus erythematosus.

Authors:  Linlin Sheng; Xiuqin Cao; Shuhong Chi; Jing Wu; Huihui Xing; Huiyu Liu; Zhiwei Yang
Journal:  Int J Mol Med       Date:  2020-08-07       Impact factor: 4.101

7.  The management of neuropsychiatric lupus in the 21st century: still so many unmet needs?

Authors:  Marcello Govoni; John G Hanly
Journal:  Rheumatology (Oxford)       Date:  2020-12-05       Impact factor: 7.580

Review 8.  Pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus: A review.

Authors:  Yuhong Liu; Zhihua Tu; Xi Zhang; Keqian Du; Zhengquan Xie; Zhiming Lin
Journal:  Front Cell Dev Biol       Date:  2022-09-05

Review 9.  Progress in the Pathogenesis and Treatment of Neuropsychiatric Systemic Lupus Erythematosus.

Authors:  Minhui Wang; Ziqian Wang; Shangzhu Zhang; Yang Wu; Li Zhang; Jiuliang Zhao; Qian Wang; Xinping Tian; Mengtao Li; Xiaofeng Zeng
Journal:  J Clin Med       Date:  2022-08-24       Impact factor: 4.964

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.